New COVID Vaccine for Clinical Trials Approved

New COVID Vaccine for Clinical Trials Approved
by Colleen Fleiss on 
April 12, 2021 at 10:16 PM
China's Sinopharm COVID-19 vaccine has recently been approved for clinical trials.
The new recombinant Covid-19 vaccine, developed by the National Vaccine & Serum Institute, a R&D centre of Sinopharm's bioscience subsidiary the China National Biotec Group (CNBG), got approval from the National Medical Products Administration on Friday, the CNBG said on its official Weibo account on Saturday, Xinhua reported.
It uses genetic engineering to grow harmless copies of the virus S-protein to induce neutralising antibodies.
‘The COVID-19 vaccine is based on the structural features of the receptor binding domain (RBD) on the virus' spike protein (S-protein).’

Related Keywords

Beijing ,China ,Mumbai ,Maharashtra ,India ,Wuhan ,Hubei ,Chinese ,Tedros Adhanom Ghebreyesus ,Products Institute Co Ltd ,China National Biotec Group ,National Health Commission ,National Medical Products Administration On ,National Vaccine Serum Institute ,Xinhua ,Wuhan Institute Of Biological Products ,National Vaccine ,Serum Institute ,National Medical Products Administration ,Wuhan Institute ,Biological Products ,Distribution Between Rich ,General Tedros Adhanom Ghebreyesus ,Effective Shot Against Mutations ,Mumbai Metropolitan Region ,Trialsclinical Trials ,Futureclinical Trials ,Placebo Effects ,Rare Insightsvaccination ,Covid 19 Vaccine ,Coronavirus Vaccination ,பெய்ஜிங் ,சீனா ,மும்பை ,மகாராஷ்டிரா ,இந்தியா ,சீன ,ப்ராடக்ட்ஸ் நிறுவனம் இணை லிமிடெட் ,சீனா தேசிய பயோடெக் குழு ,தேசிய ஆரோக்கியம் தரகு ,தேசிய தடுப்பூசி சீரம் நிறுவனம் ,தேசிய தடுப்பூசி ,சீரம் நிறுவனம் ,உயிரியல் ப்ராடக்ட்ஸ் ,மும்பை பெருநகர பகுதி ,மருந்துப்போலி விளைவுகள் ,